Correlation between gynecomastia and endocrine regulation in patients with metabolic dysfunction-associated fatty liver disease: A cross-sectional study

Table 3 The correlation between metabolic dysfunction-associated fatty liver disease and gynecomastia after adjustments

Metabolic dysfunction-associated fatty liver disease	Nonadjusted		Model I		Model II
	OR (95%CI)	P value	OR (95%CI)	P value	OR (95%CI)	P value
Mild	Reference		Reference		Reference
Moderate	1.523 (1.176-1.793)	0.040	1.600 (1.107-1.835)	0.046	1.256 (0.874-1.732)	0.229
Severe	3.627 (2.500-5.263)	< 0.001	3.157 (2.056-4.847)	< 0.001	1.873 (1.038-3.381)	0.037

Model I adjusting for age, hypertension, diabetes mellitus (DM), sporting, smoking, body mass index (BMI) , waist-to-hip ratio (WHR). Model II adjusting for age, hypertension, DM, sporting, smoking, BMI, WHR, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, creatinine, uric acid, high-density lipoprotein, low-density lipoprotein, total bilirubin, total protein, estradiol, testosterone, estrogen/androgen ratio. OR: Odds ratio.